Journal article
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length
Leukemia & Lymphoma, Vol.59(3), pp.643-649
03/04/2018
DOI: 10.1080/10428194.2017.1349905
PMCID: PMC5769448
PMID: 28718694
Abstract
We hypothesized that the length of treatment-free survival following (a) initial diagnosis and (b) first-line treatment would be associated with improved subsequent five-year relative survival (RS5) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). 19,879 patients incident CLL/SLL cases (median age = 76 years) were identified from SEER-Medicare. RS5 improved from 0.73 (95% CI: 0.72, 0.74) at diagnosis to 0.81 (95% CI: 0.80, 0.82) at year 1 and 0.89 (95% CI: 0.83, 0.96) at year 10 among those who had not received treatment. In our analysis of survival patterns following first-line treatment, RS5 improved from 0.55 (95% CI: 0.53, 0.57) at initiation of first-line treatment to 0.84 (95% CI: 0.75, 0.92) among patients who had not been retreated at year 5 following first-line therapy. Longer periods of treatment-free survival following initial diagnosis and first-line treatment were both predictive of meaningfully improved prognosis in CLL/SLL patients.
Details
- Title: Subtitle
- Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length
- Creators
- Eric M Ammann - Holden Comprehensive Cancer Center, University of IowaTait D Shanafelt - Department of Internal Medicine, Mayo ClinicKara B Wright - Holden Comprehensive Cancer Center, University of IowaBradley D McDowell - Holden Comprehensive Cancer Center, University of IowaBrian K Link - Department of Internal Medicine, Carver College of Medicine, University of IowaElizabeth A Chrischilles - Holden Comprehensive Cancer Center, University of Iowa
- Resource Type
- Journal article
- Publication Details
- Leukemia & Lymphoma, Vol.59(3), pp.643-649
- DOI
- 10.1080/10428194.2017.1349905
- PMID
- 28718694
- PMCID
- PMC5769448
- NLM abbreviation
- Leuk Lymphoma
- ISSN
- 1042-8194
- eISSN
- 1029-2403
- Publisher
- Taylor & Francis
- Grant note
- P50 CA097274 / National Cancer Institute P30 CA086862 / University of Iowa
- Language
- English
- Date published
- 03/04/2018
- Academic Unit
- Pharmacy; Epidemiology; Holden Comprehensive Cancer Center; Internal Medicine
- Record Identifier
- 9983995050802771
Metrics
19 Record Views